SBIR TOPIC 417; PHASE I; FIRM FIXED PRICEDELIVERY: 06/14/2022PERIOD OF PERFORMANCE: 09/15/2021 TO 12/14/2022

It was estimated that ~170,000 patients diagnosed with Brain metastases (BMs) in United States each year and most patients have clinical manifestation of multiple BMs (mBMs). Stereotactic radiosurgery (SRS) has been used frequently for treating mBMs and demonstrated much less toxicity than conventional whole brain radiotherapy. Current SRS platform was designed for single-fraction treatment on limited number of targets, thus clinical workflow of mBMs SRS using extant platform is cumbersome: 1) labor-intensive manual mBMs identification and segmentation; 2) cumbersome manual planning mBMs into different treatment sessions; and 3) tedious tracking mBMs changes in treatment follow-up. Our team have been actively developing (R01-supported) an Artificial intelligence (AI)-based mBMs management platform, namely AimBMs, to optimize SRS mBMs patient care. This SBIR proposal targets to translate, validate and commercialize the AimBMs platform. The proposal consists of three aims: 1) develop a private cloud to integrate AimBMs platform into clinical practice environment; 2) refine and optimize AimBMs platform performance for site-specific practice using on-site incremental learning; and 3) validate AimBMs platform performance in 5 collaborating institutes. The success of this project will lead to bringing the AimBMs platform from a single academic institution use to a broad SRS community practice, benefitting a large mBMs population.